LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson’s disease

Selective neuronal vulnerability in Parkinson disease

(2017) D. James Surmeier et al.   NATURE REVIEWS NEUROSCIENCE

Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance

(2016) Dena G. Hernandez et al.   JOURNAL OF NEUROCHEMISTRY

Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease

(2016) Kyle B. Fraser et al.   MOVEMENT DISORDERS

A unifying mechanism in neurodegeneration

(2016) Christopher A. Ross et al.   NATURE

XRCC1 mutation is associated with PARP1 hyperactivation and cerebellar ataxia

(2016) Nicolas C. Hoch et al.   NATURE

Mitochondrial DNA exhibits resistance to induced point and deletion mutations

(2016) William J. Valente et al.   NUCLEIC ACIDS RESEARCH

Inhibitor treatment of peripheral mononuclear cells from Parkinson’s disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker

(2016) G. Perera et al.   Scientific Reports

Digital PCR methods improve detection sensitivity and measurement precision of low abundance mtDNA deletions

(2016) Frances R. Belmonte et al.   Scientific Reports

Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases

(2016) Martin Steger et al.   eLife

Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation

(2016) E. Lobbestael et al.   Scientific Reports

Inhibitors of Leucine-Rich Repeat Kinase 2 (LRRK2): Progress and Promise for the Treatment of Parkinson’s Disease

(2015) Paul Gilligan   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Fibroblast Biomarkers of Sporadic Parkinson’s Disease and LRRK2 Kinase Inhibition

(2015) G. A. Smith et al.   MOLECULAR NEUROBIOLOGY

Effect of selective LRRK2 kinase inhibition on nonhuman primate lung

(2015) Reina N. Fuji et al.   Science Translational Medicine

VPS35 Deficiency or Mutation Causes Dopaminergic Neuronal Loss by Impairing Mitochondrial Fusion and Function

(2015) Fu-Lei Tang et al.   Cell Reports

Clinical Correlations With Lewy Body Pathology inLRRK2-Related Parkinson Disease

(2015) Lorraine V. Kalia et al.   JAMA Neurology

Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 – 2013)

(2014) Raghava R Kethiri et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

LRRK2 pathobiology in Parkinson's disease

(2014) Ian Martin et al.   JOURNAL OF NEUROCHEMISTRY

Interferon-γ induces leucine-rich repeat kinase LRRK2 via extracellular signal-regulated kinase ERK5 in macrophages

(2014) Martin Kuss et al.   JOURNAL OF NEUROCHEMISTRY

Mutant LRRK2 Toxicity in Neurons Depends on LRRK2 Levels and Synuclein But Not Kinase Activity or Inclusion Bodies

(2014) G. Skibinski et al.   JOURNAL OF NEUROSCIENCE

Ten Years and Counting: Moving Leucine-Rich RepeatKinase 2 Inhibitors to the Clinic

(2014) Andrew B. West   MOVEMENT DISORDERS

Mitochondrial DNA damage: Molecular marker of vulnerable nigral neurons in Parkinson's disease

(2014) Laurie H. Sanders et al.   NEUROBIOLOGY OF DISEASE

Mitochondrial DNA Damage as a Peripheral Biomarker for Mitochondrial Toxin Exposure in Rats

(2014) Laurie H. Sanders et al.   TOXICOLOGICAL SCIENCES

Phosphorylation of LRRK2 by casein kinase 1α regulates trans-Golgi clustering via differential interaction with ARHGEF7

(2014) Ruth Chia et al.   Nature Communications

LRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site status

(2014) April Reynolds et al.   Frontiers in Molecular Neuroscience

The development of CNS-active LRRK2 inhibitors using property-directed optimisation

(2013) Madeline E. Kavanagh et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Genetic Correction of a LRRK2 Mutation in Human iPSCs Links Parkinsonian Neurodegeneration to ERK-Dependent Changes in Gene Expression

(2013) Peter Reinhardt et al.   Cell Stem Cell

Oxidative damage to macromolecules in human Parkinson disease and the rotenone model

(2013) Laurie H. Sanders et al.   FREE RADICAL BIOLOGY AND MEDICINE

Axonal Degeneration of Nigra-striatum Dopaminergic Neurons Induced by 1-Methyl-4-phenyl-1,2,3, 6-tetrahydropyridine in Mice

(2013) L-H Li et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: Reversal by gene correction

(2013) Laurie H. Sanders et al.   NEUROBIOLOGY OF DISEASE

The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation

(2012) Iakov N. Rudenko et al.   BIOCHEMICAL JOURNAL

Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 – 2011)

(2012) Xianming Deng et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity

(2012) C. Yao et al.   HUMAN MOLECULAR GENETICS

Automated imaging system for fast quantitation of neurons, cell morphology and neurite morphometry in vivo and in vitro

(2012) Victor Tapias et al.   NEUROBIOLOGY OF DISEASE

Screening for Novel LRRK2 Inhibitors Using a High-Throughput TR-FRET Cellular Assay for LRRK2 Ser935 Phosphorylation

(2012) Spencer B. Hermanson et al.   PLoS One

Ser1292 Autophosphorylation Is an Indicator of LRRK2 Kinase Activity and Contributes to the Cellular Effects of PD Mutations

(2012) Z. Sheng et al.   Science Translational Medicine

Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells from Patients with Familial Parkinson's Disease

(2012) O. Cooper et al.   Science Translational Medicine

Brain Penetrant LRRK2 Inhibitor

(2012) Hwan Geun Choi et al.   ACS Medicinal Chemistry Letters

Discovery of a Highly Selective, Brain-Penetrant Aminopyrazole LRRK2 Inhibitor

(2012) Bryan K. Chan et al.   ACS Medicinal Chemistry Letters

Single-Cell Redox Imaging Demonstrates a Distinctive Response of Dopaminergic Neurons to Oxidative Insults

(2011) Maxx P. Horowitz et al.   ANTIOXIDANTS & REDOX SIGNALING

Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson’s disease mutations and LRRK2 pharmacological inhibition

(2011) Elizabeth A. Doggett et al.   JOURNAL OF NEUROCHEMISTRY

DJ-1 knock-down impairs astrocyte mitochondrial function

(2011) N.J. Larsen et al.   NEUROSCIENCE

DNA repair deficiency in neurodegeneration

(2011) Dennis Kjølhede Jeppesen et al.   PROGRESS IN NEUROBIOLOGY

Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization

(2010) Nicolas Dzamko et al.   BIOCHEMICAL JOURNAL

Bioenergetics of neurons inhibit the translocation response of Parkin following rapid mitochondrial depolarization

(2010) Victor S. Van Laar et al.   HUMAN MOLECULAR GENETICS

Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease

(2010) Byoung Dae Lee et al.   NATURE MEDICINE

On Mitochondria, Mutations, and Methodology

(2009) Marc Vermulst et al.   Cell Metabolism

The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson’s disease

(2009) Teresa G. Hastings   JOURNAL OF BIOENERGETICS AND BIOMEMBRANES